Oncomine Dx Target Test
FDA-approved targeted NGS oncology companion diagnostic platform.
- Developer
- Thermo Fisher Scientific
- Intended use
- Other
- Cancer scope
- Non-small cell lung cancer, Thyroid cancer
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA mutation, RNA
- Current version
- Oncomine Dx Target Test P160045 current FDA lineage (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 4 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.